Genmab A/S (GMAB.CO)

DKK 1486.5

(4.13%)

EBITDA Summary of Genmab A/S

  • Genmab A/S's latest annual EBITDA in 2023 was 5.56 Billion DKK , down -6.93% from previous year.
  • Genmab A/S's latest quarterly EBITDA in 2024 Q2 was 2.1 Billion DKK , up 24.55% from previous quarter.
  • Genmab A/S reported an annual EBITDA of 7.25 Billion DKK in 2022, up 103.38% from previous year.
  • Genmab A/S reported an annual EBITDA of 4.24 Billion DKK in 2021, down -48.74% from previous year.
  • Genmab A/S reported a quarterly EBITDA of 1.09 Billion DKK for 2024 Q1, up 84.87% from previous quarter.
  • Genmab A/S reported a quarterly EBITDA of 1.96 Billion DKK for 2023 Q4, up 0.26% from previous quarter.

Annual EBITDA Chart of Genmab A/S (2023 - 2002)

Historical Annual EBITDA of Genmab A/S (2023 - 2002)

Year EBITDA EBITDA Growth
2023 5.56 Billion DKK -6.93%
2022 7.25 Billion DKK 103.38%
2021 4.24 Billion DKK -48.74%
2020 6.16 Billion DKK 133.21%
2019 2.77 Billion DKK 70.41%
2018 1.69 Billion DKK 49.61%
2017 1.11 Billion DKK -3.0%
2016 1.17 Billion DKK 48.38%
2015 789.46 Million DKK 151.64%
2014 313.73 Million DKK 155.9%
2013 80.91 Million DKK 125.98%
2012 -96.24 Million DKK 11.35%
2011 -192.74 Million DKK -121.89%
2010 -100 Million DKK 73.23%
2009 -317.26 Million DKK -1.89%
2008 -879.41 Million DKK -138.99%
2007 -367.96 Million DKK 12.33%
2006 -419.7 Million DKK -16.43%
2005 -360.46 Million DKK -23.04%
2004 -367.96 Million DKK -62.94%
2003 -179.8 Million DKK -126.85%
2002 669.75 Million DKK 0.0%

Peer EBITDA Comparison of Genmab A/S

Name EBITDA EBITDA Difference
ALK-Abelló A/S 913 Million DKK -509.091%
Bavarian Nordic A/S 2.05 Billion DKK -171.032%
Gubra A/S -28.89 Million DKK 19345.544%
Novo Nordisk A/S 113.33 Billion DKK 95.093%
Orphazyme A/S -26.04 Million DKK 21449.048%
Pharma Equity Group A/S -24.79 Million DKK 22524.291%
Zealand Pharma A/S -651.58 Million DKK 953.464%